The U.S. Senate gave unanimous approval to a bipartisan bill to “cut the red tape” that stalls scientific research into the medical properties of cannabis and cannabidiols.
The measure – which would authorize the U.S. Food and Drug Administration to study cannabis products – now heads to the U.S. House of Representatives for consideration.
S. 253 was co-sponsored by Iowa Republican Sen. Chuck Grassley and Hawaii Democrat Brian Schatz, who both lauded the bill’s success.
“This bipartisan bill is critical to better understanding the marijuana plant and its potential benefits and side effects,” Grassley said in the release.
Business leaders need reliable industry data and in-depth analysis to make smart investments and informed decisions in these uncertain economic times.
Order your 2022 MJBiz Factbook, out now!
- 200+ pages and 50 charts with key data points
- State-by-state guide to regulations, taxes & opportunities
- Segmented research reports for the marijuana + hemp industries
- Accurate financial forecasts + investment trends
Stay ahead of the curve and avoid costly missteps in the rapidly evolving cannabis industry.
“It will empower the FDA to analyze CBD and medical marijuana products in a safe and responsible way so that the American public can decide whether to utilize them in the future based on sound scientific data.”
The Senate measure comes almost a year after the U.S. Drug Enforcement Administration signaled it might ease its restrictions on marijuana research.